Table 7.

Odds ratios of NOACs vs warfarin in meta-analysis.

	Standard dose NOACs			Low dose NOACs
	Asian	Non-Asian	Interaction P value	Asian	Non-Asian	Interaction P value
Stroke/SEE	0.65	0.85	0.045	0.93	1.07	0.353
	(0.52–0.83)	(0.77–0.93)		(0.71–1.21)	(0.93–1.24)
Ischemic stroke	0.89	0.95	0.673	1.06	1.29	0.504
	(0.67–1.17)	(0.84–1.06)		(0.68–1.65)	(0.88–1.90)
Myocardial infarction	0.97	0.98	0.977	0.92	1.28	0.352
	(0.59–1.58)	(0.82–1.12)		(0.48–1.79)	(1.06–1.55)
All-cause mortality	0.80	0.91	0.219	0.89	0.88)	0.934
	(0.65–0.98)	(0.86–0.97)		(0.70–1.15)	(0.81–0.96
Major bleeding	0.57	0.89	0.004	0.52	0.64	0.579
	(0.44–0.74)	(0.76–1.04)		(0.32–0.86)	(0.38–1.09)
Intra-cranial hemorrhage	0.33	0.52	0.059	0.28	0.32	0.661
	(0.22–0.50)	(0.42–0.64)		(0.16–0.49)	(0.24–0.44)
Hemorrhagic stroke	0.32	0.56	0.046	0.35	0.34	0.944
	(0.19–0.52)	(0.44–0.70)		(0.18–0.68)	(0.23–0.50)
GI bleeding	0.79	1.44	0.041	0.67	0.87	0.460
	(0.48–1.32)	(1.12–1.85)		(0.39–1.15)	(0.56–1.35)

GI: gastrointestinal; NOACs: non-vitamin K antagonist oral anticoagulants; SEE: systemic embolization event